Scientific Reports (Oct 2023)

Superior performance of biofilm versus planktonic Limosilactobacillus reuteri in protection of the intestines and brain in a piglet model of necrotizing enterocolitis

  • Samantha J. Wala,
  • Nitin Sajankila,
  • Mecklin V. Ragan,
  • Audrey F. Duff,
  • Joseph Wickham,
  • Samuel G. Volpe,
  • Yijie Wang,
  • Miriam Conces,
  • Zachary Dumbauld,
  • Nanditha Purayil,
  • Siddharth Narayanan,
  • Adrian Rajab,
  • Belgacem Mihi,
  • Michael T. Bailey,
  • Steven D. Goodman,
  • Gail E. Besner

DOI
https://doi.org/10.1038/s41598-023-44676-5
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 16

Abstract

Read online

Abstract Necrotizing enterocolitis (NEC) is the leading cause of gastrointestinal-related death in premature infants. Its etiology is multifactorial, with intestinal dysbiosis playing a major role. Probiotics are a logical preventative therapy for NEC, however their benefits have been inconsistent. We previously developed a novel probiotic delivery system in which planktonic (free-living) Limosilactobacillus reuteri (Lr) is incubated with biocompatible dextranomer microspheres (DM) loaded with maltose (Lr-DM-maltose) to induce biofilm formation. Here we have investigated the effects of Lr-DM-maltose in an enteral feed-only piglet model of NEC. We found a significant decrease in the incidence of Definitive NEC (D-NEC), death associated with D-NEC, and activated microglia in the brains of piglets treated with Lr-DM-maltose compared to non-treated piglets. Microbiome analyses using 16S rRNA sequencing of colonic contents revealed a significantly different microbial community composition between piglets treated with Lr-DM-maltose compared to non-treated piglets, with an increase in Lactobacillaceae and a decrease in Clostridiaceae in Lr-DM-maltose-treated piglets. Furthermore, there was a significant decrease in the incidence of D-NEC between piglets treated with Lr-DM-maltose compared to planktonic Lr. These findings validate our previous results in rodents, and support future clinical trials of Lr in its biofilm state for the prevention of NEC in premature neonates.